ANG Lifesciences India Past Earnings Performance
Past criteria checks 0/6
ANG Lifesciences India's earnings have been declining at an average annual rate of -3.1%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 14.5% per year.
Key information
-3.1%
Earnings growth rate
-2.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 14.5% |
| Return on equity | -12.9% |
| Net Margin | -7.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How ANG Lifesciences India makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,477 | -111 | 214 | 0 |
| 30 Sep 23 | 1,761 | -69 | 223 | 0 |
| 30 Jun 23 | 2,026 | -20 | 235 | 0 |
| 31 Mar 23 | 2,199 | -3 | 243 | 0 |
| 31 Dec 22 | 2,758 | 96 | 241 | 0 |
| 30 Sep 22 | 2,785 | 136 | 244 | 0 |
| 30 Jun 22 | 3,081 | 238 | 230 | 0 |
| 31 Mar 22 | 3,543 | 403 | 215 | 0 |
| 31 Dec 21 | 2,950 | 364 | 189 | 0 |
| 30 Sep 21 | 2,836 | 353 | 170 | 0 |
| 30 Jun 21 | 2,312 | 243 | 154 | 0 |
| 31 Mar 21 | 1,544 | 70 | 140 | 0 |
| 31 Dec 20 | 1,524 | 73 | 135 | 0 |
| 30 Sep 20 | 1,543 | 88 | 113 | 0 |
| 30 Jun 20 | 1,406 | 74 | 96 | 0 |
| 31 Mar 20 | 1,268 | 61 | 83 | 0 |
| 31 Dec 19 | 1,264 | 59 | 75 | 0 |
| 30 Sep 19 | 1,260 | 58 | 62 | 0 |
| 30 Jun 19 | 1,238 | 57 | 65 | 0 |
| 31 Mar 19 | 1,217 | 56 | 72 | 0 |
| 31 Dec 18 | 1,114 | 55 | 67 | 0 |
| 30 Sep 18 | 1,012 | 54 | 62 | 0 |
| 30 Jun 18 | 886 | 46 | 60 | 0 |
| 31 Mar 18 | 760 | 37 | 58 | 0 |
| 31 Dec 17 | 716 | 31 | 53 | 0 |
| 30 Sep 17 | 672 | 25 | 46 | 0 |
| 30 Jun 17 | 675 | 27 | 44 | 0 |
| 31 Mar 17 | 677 | 28 | 43 | 0 |
| 31 Mar 16 | 551 | 17 | 35 | 0 |
| 31 Mar 15 | 369 | 4 | 24 | 0 |
| 31 Mar 14 | 346 | 2 | 12 | 0 |
Quality Earnings: 540694 is currently unprofitable.
Growing Profit Margin: 540694 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 540694 is unprofitable, and losses have increased over the past 5 years at a rate of 3.1% per year.
Accelerating Growth: Unable to compare 540694's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 540694 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 540694 has a negative Return on Equity (-12.95%), as it is currently unprofitable.